T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun Vasant Balar,Daniel Castellano,Peter H. O'Donnell,Petros Grivas,Jacqueline Vuky,Thomas Powles,Elizabeth R. Plimack,Noah M. Hahn,Ronald de Wit,Lei Pang,Mary J. Savage,Rodolfo F. Perini,Stephen Michael Keefe,Dean F. Bajorin,Joaquim Bellmunt +14 more
TL;DR: First-line pembrolizumab has antitumour activity and acceptable tolerability in cisplatin-ineligible patients with urothelial cancer, most of whom were elderly, had poor prognostic factors, or had serious comorbidities.
Journal ArticleDOI
Overview of the main outcomes in breast-cancer prevention trials.
Jack Cuzick,Thomas Powles,Umberto Veronesi,John F. Forbes,Robert Edwards,Stanley W. Ashley,Peter Boyle +6 more
TL;DR: Although tamoxifen cannot yet be recommended as a preventive agent (except possibly in women at very high risk with a low risk of side-effects), continued follow-up of the current trials is essential for identification of a subgroup of high-risk, healthy women for whom the risk-benefit ratio is sufficiently positive.
Journal ArticleDOI
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.
Lennard Y W Lee,Jean-Baptiste Cazier,Vasileios Angelis,Roland Arnold,Vartika Bisht,Naomi A. Campton,Julia Chackathayil,Vinton Cheng,Helen Curley,Matthew W. Fittall,Luke Freeman-Mills,Spyridon Gennatas,Anshita Goel,Simon Hartley,D.J. Hughes,David J. Kerr,Alvin J.X. Lee,Rebecca Lee,Sophie McGrath,Christopher P. Middleton,N. Murugaesu,Thomas Newsom-Davis,Alicia Okines,Anna Olsson-Brown,Claire Palles,Yi Pan,Ruth Pettengell,Thomas Powles,Emily A. Protheroe,Karin Purshouse,Archana Sharma-Oates,Shivan Sivakumar,Ashley J. Smith,Thomas Starkey,Chris D. Turnbull,Csilla Várnai,Nadia Yousaf,Rachel Kerr,Gary Middleton +38 more
TL;DR: The clinical and demographic characteristics and COVID-19 outcomes in patients with cancer appear to be principally driven by age, gender, and comorbidities.
Journal ArticleDOI
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott,Mahrukh Huseni,Michael B. Atkins,Robert J. Motzer,Brian I. Rini,Bernard Escudier,Lawrence Fong,Richard W. Joseph,Sumanta K. Pal,James A. Reeves,Mario Sznol,John D. Hainsworth,W. Kimryn Rathmell,Walter M. Stadler,Thomas E. Hutson,Martin Gore,Alain Ravaud,Sergio Bracarda,Cristina Suarez,Riccardo Danielli,Viktor Gruenwald,Toni K. Choueiri,Dorothee Nickles,Suchit Jhunjhunwala,Elisabeth Piault-Louis,Alpa Thobhani,Jiaheng Qiu,Daniel S. Chen,Priti S. Hegde,Christina Schiff,Gregg Fine,Thomas Powles +31 more
TL;DR: Molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.
Journal ArticleDOI
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Toni K. Choueiri,Thomas Powles,Mauricio Burotto,Bernard Escudier,Maria T Bourlon,B. Zurawski,Victor M. Oyervides Juárez,James J. Hsieh,Umberto Basso,Amishi Yogesh Shah,Cristina Suárez,Alketa Hamzaj,Jeffrey C. Goh,Carlos Barrios,Martin Eduardo Richardet,C. Porta,Ruben Dario Kowalyszyn,Juan P. Feregrino,Jakub Żołnierek,David Pook,Elizabeth R. Kessler,Yoshihiko Tomita,Ryuichi Mizuno,Jens Bedke,Joshua Zhang,Matthew Maurer,Burcin Simsek,Flavia Ejzykowicz,Gisela Schwab,Andrea B. Apolo,Robert J. Motzer +30 more
TL;DR: Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with previously untreated advanced renal-cell carcinoma.